Bristol-Myers Squibb Targets Autism Irritability With New Phase 3 Drug Trial

Bristol-Myers Squibb announced it is launching a Phase 3 trial to test a drug combination to treat autism irritability. The goal is to see if the drug combo KarXT (Xanomeline/Trospium Chloride) plus KarX-EC (Xanomeline Enteric-coated) can safely alleviate irritability in young people with autism.

The trial will test a random selection of participants who receive either a combination of two oral drugs, KarXT and KarX-EC, or a matched placebo. Both are designed to be taken on set days and doses to manage irritability linked to autism. The aim is to offer better symptom control with . . .